Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Kline, Christina Leah B., El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817731/
https://www.ncbi.nlm.nih.gov/pubmed/24276379
http://dx.doi.org/10.3390/ph6080988
_version_ 1782478119021576192
author Kline, Christina Leah B.
El-Deiry, Wafik S.
author_facet Kline, Christina Leah B.
El-Deiry, Wafik S.
author_sort Kline, Christina Leah B.
collection PubMed
description The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety of these chemotherapeutics. In addition, we discuss how alternate pharmaceuticals have been developed in light of a potential lack of response or resistance to a particular chemotherapeutic.
format Online
Article
Text
id pubmed-3817731
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38177312013-11-14 Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action Kline, Christina Leah B. El-Deiry, Wafik S. Pharmaceuticals (Basel) Review The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety of these chemotherapeutics. In addition, we discuss how alternate pharmaceuticals have been developed in light of a potential lack of response or resistance to a particular chemotherapeutic. MDPI 2013-08-21 /pmc/articles/PMC3817731/ /pubmed/24276379 http://dx.doi.org/10.3390/ph6080988 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Kline, Christina Leah B.
El-Deiry, Wafik S.
Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
title Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
title_full Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
title_fullStr Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
title_full_unstemmed Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
title_short Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
title_sort personalizing colon cancer therapeutics: targeting old and new mechanisms of action
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817731/
https://www.ncbi.nlm.nih.gov/pubmed/24276379
http://dx.doi.org/10.3390/ph6080988
work_keys_str_mv AT klinechristinaleahb personalizingcoloncancertherapeuticstargetingoldandnewmechanismsofaction
AT eldeirywafiks personalizingcoloncancertherapeuticstargetingoldandnewmechanismsofaction

Ejemplares similares